Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Herceptin Adjuvant (HERA) Trial Study Team; Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber

doi:10.1056/NEJMoa052306

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Herceptin Adjuvant (HERA) Trial Study Team, Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H Barrios, Günther Steger, Chiun-Shen Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István LángUlrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas M Suter, Josef Rüschoff, Tamás Suto, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, M Stella Dolci, Richard D Gelber

Research output: Contribution to journal › Article › peer-review

Abstract

Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy.

Original language	English
Pages (from-to)	1659-72
Number of pages	14
Journal	New England Journal of Medicine
Volume	353
Issue number	16
DOIs	https://doi.org/10.1056/NEJMoa052306
Publication status	Published - 20 Oct 2005

Keywords / Materials (for Non-textual outputs)

Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Breast Neoplasms
Chemotherapy, Adjuvant
Combined Modality Therapy
Disease-Free Survival
Female
Heart Diseases
Humans
Middle Aged
Receptor, erbB-2
Recurrence
Survival Analysis

Access to Document

10.1056/NEJMoa052306

Cite this

Herceptin Adjuvant (HERA) Trial Study Team, Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C. H., Steger, G., Huang, C.-S., Andersson, M., Inbar, M., Lichinitser, M., ... Gelber, R. D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353(16), 1659-72. https://doi.org/10.1056/NEJMoa052306

@article{9fd6d54e29fa4a1c85ecb34979ff5b41,

title = "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer",

abstract = "Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy.",

keywords = "Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Breast Neoplasms, Chemotherapy, Adjuvant, Combined Modality Therapy, Disease-Free Survival, Female, Heart Diseases, Humans, Middle Aged, Receptor, erbB-2, Recurrence, Survival Analysis",

author = "{Herceptin Adjuvant (HERA) Trial Study Team} and Piccart-Gebhart, {Martine J} and Marion Procter and Brian Leyland-Jones and Aron Goldhirsch and Michael Untch and Ian Smith and Luca Gianni and Jose Baselga and Richard Bell and Christian Jackisch and David Cameron and Mitch Dowsett and Barrios, {Carlos H} and G{\"u}nther Steger and Chiun-Shen Huang and Michael Andersson and Moshe Inbar and Mikhail Lichinitser and Istv{\'a}n L{\'a}ng and Ulrike Nitz and Hiroji Iwata and Christoph Thomssen and Caroline Lohrisch and Suter, {Thomas M} and Josef R{\"u}schoff and Tam{\'a}s Suto and Victoria Greatorex and Carol Ward and Carolyn Straehle and Eleanor McFadden and Dolci, {M Stella} and Gelber, {Richard D}",

year = "2005",

month = oct,

day = "20",

doi = "10.1056/NEJMoa052306",

language = "English",

volume = "353",

pages = "1659--72",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOC",

number = "16",

}

Herceptin Adjuvant (HERA) Trial Study Team, Piccart-Gebhart, MJ, Procter, M, Leyland-Jones, B, Goldhirsch, A, Untch, M, Smith, I, Gianni, L, Baselga, J, Bell, R, Jackisch, C, Cameron, D, Dowsett, M, Barrios, CH, Steger, G, Huang, C-S, Andersson, M, Inbar, M, Lichinitser, M, Láng, I, Nitz, U, Iwata, H, Thomssen, C, Lohrisch, C, Suter, TM, Rüschoff, J, Suto, T, Greatorex, V, Ward, C, Straehle, C, McFadden, E, Dolci, MS & Gelber, RD 2005, 'Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer', New England Journal of Medicine, vol. 353, no. 16, pp. 1659-72. https://doi.org/10.1056/NEJMoa052306

TY - JOUR

T1 - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

AU - Herceptin Adjuvant (HERA) Trial Study Team

AU - Piccart-Gebhart, Martine J

AU - Procter, Marion

AU - Leyland-Jones, Brian

AU - Goldhirsch, Aron

AU - Untch, Michael

AU - Smith, Ian

AU - Gianni, Luca

AU - Baselga, Jose

AU - Bell, Richard

AU - Jackisch, Christian

AU - Cameron, David

AU - Dowsett, Mitch

AU - Barrios, Carlos H

AU - Steger, Günther

AU - Huang, Chiun-Shen

AU - Andersson, Michael

AU - Inbar, Moshe

AU - Lichinitser, Mikhail

AU - Láng, István

AU - Nitz, Ulrike

AU - Iwata, Hiroji

AU - Thomssen, Christoph

AU - Lohrisch, Caroline

AU - Suter, Thomas M

AU - Rüschoff, Josef

AU - Suto, Tamás

AU - Greatorex, Victoria

AU - Ward, Carol

AU - Straehle, Carolyn

AU - McFadden, Eleanor

AU - Dolci, M Stella

AU - Gelber, Richard D

PY - 2005/10/20

Y1 - 2005/10/20

N2 - Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy.

AB - Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy.

KW - Adult

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Agents

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Female

KW - Heart Diseases

KW - Humans

KW - Middle Aged

KW - Receptor, erbB-2

KW - Recurrence

KW - Survival Analysis

U2 - 10.1056/NEJMoa052306

DO - 10.1056/NEJMoa052306

M3 - Article

C2 - 16236737

SN - 0028-4793

VL - 353

SP - 1659

EP - 1672

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 16

ER -

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this